MDMB-FUBICA: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:MDMB-FUBICA}} | |||
== | ==Overview== | ||
[[File:MDMB_FUBICA.png|thumb|right|Chemical structure of MDMB-FUBICA]] | |||
'''MDMB-FUBICA''' is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the [[cannabinoid receptor]]s, primarily acting on the [[CB1 receptor]]. MDMB-FUBICA is part of a class of compounds that are often found in [[synthetic cannabis]] products, which are marketed as legal alternatives to [[cannabis]]. | |||
MDMB-FUBICA is | ==Chemical Structure== | ||
MDMB-FUBICA is chemically classified as an indole-3-carboxamide. Its full chemical name is methyl (S)-2-[[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate. The compound features a fluorobutyl side chain, which is a common modification in synthetic cannabinoids to enhance their potency and affinity for cannabinoid receptors. | |||
==Pharmacology== | ==Pharmacology== | ||
MDMB-FUBICA acts as a full agonist at the CB1 receptor, which is primarily responsible for the psychoactive effects of cannabinoids. The activation of CB1 receptors by MDMB-FUBICA can lead to effects similar to those of [[tetrahydrocannabinol]] (THC), the main psychoactive component of cannabis. These effects can include euphoria, altered perception, and relaxation, but also anxiety, paranoia, and other adverse effects. | |||
MDMB-FUBICA acts as a | |||
==Legal Status== | ==Legal Status== | ||
Due to its potential for abuse and lack of medical use, MDMB-FUBICA has been classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and "[[new psychoactive substances]]" (NPS). | |||
==Health Risks== | ==Health Risks== | ||
The use of MDMB-FUBICA, like other synthetic cannabinoids, has been associated with a range of adverse health effects. These can include [[tachycardia]], [[hypertension]], [[nausea]], [[vomiting]], [[hallucinations]], and [[seizures]]. In some cases, severe toxicity and fatalities have been reported. | |||
==Synthesis and Detection== | |||
The synthesis of MDMB-FUBICA involves the reaction of indole derivatives with appropriate carboxylic acid derivatives. Detection of MDMB-FUBICA in biological samples can be challenging due to its structural similarity to other synthetic cannabinoids. Advanced analytical techniques such as [[mass spectrometry]] and [[gas chromatography]] are often employed for its identification. | |||
==Related pages== | |||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[ | * [[Cannabinoid receptor]] | ||
* [[ | * [[New psychoactive substances]] | ||
* [[ | * [[Tetrahydrocannabinol]] | ||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Designer drugs]] | ||
Latest revision as of 03:45, 13 February 2025
Overview[edit]
MDMB-FUBICA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, primarily acting on the CB1 receptor. MDMB-FUBICA is part of a class of compounds that are often found in synthetic cannabis products, which are marketed as legal alternatives to cannabis.
Chemical Structure[edit]
MDMB-FUBICA is chemically classified as an indole-3-carboxamide. Its full chemical name is methyl (S)-2-[[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate. The compound features a fluorobutyl side chain, which is a common modification in synthetic cannabinoids to enhance their potency and affinity for cannabinoid receptors.
Pharmacology[edit]
MDMB-FUBICA acts as a full agonist at the CB1 receptor, which is primarily responsible for the psychoactive effects of cannabinoids. The activation of CB1 receptors by MDMB-FUBICA can lead to effects similar to those of tetrahydrocannabinol (THC), the main psychoactive component of cannabis. These effects can include euphoria, altered perception, and relaxation, but also anxiety, paranoia, and other adverse effects.
Legal Status[edit]
Due to its potential for abuse and lack of medical use, MDMB-FUBICA has been classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and "new psychoactive substances" (NPS).
Health Risks[edit]
The use of MDMB-FUBICA, like other synthetic cannabinoids, has been associated with a range of adverse health effects. These can include tachycardia, hypertension, nausea, vomiting, hallucinations, and seizures. In some cases, severe toxicity and fatalities have been reported.
Synthesis and Detection[edit]
The synthesis of MDMB-FUBICA involves the reaction of indole derivatives with appropriate carboxylic acid derivatives. Detection of MDMB-FUBICA in biological samples can be challenging due to its structural similarity to other synthetic cannabinoids. Advanced analytical techniques such as mass spectrometry and gas chromatography are often employed for its identification.
